ClinConnect ClinConnect Logo
Search / Trial NCT05611242

Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Launched by MERCY HEALTH OHIO · Nov 2, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Stroke Ischemic Stroke Thrombectomy

ClinConnect Summary

This clinical trial is studying a treatment for patients who have experienced an acute ischemic stroke, which is caused by a blockage in a blood vessel that supplies the brain. The trial aims to find out if a specific procedure, called intra-arterial mechanical thrombectomy combined with stenting, is more effective than other approaches for patients with blockages in both the carotid artery and the brain's blood vessels. Participants will be randomly assigned to one of the treatment options, and the study is currently looking for individuals aged 18 to 79 who show symptoms of stroke and have certain imaging results indicating a blockage.

To be eligible for the trial, participants must have experienced stroke symptoms and meet specific imaging criteria that show significant artery blockages. They should be able to start treatment within 16 hours of their stroke onset and have a good level of function before the stroke occurred. Participants can expect to receive one of the two treatments and will be closely monitored throughout the trial. It’s important to know that certain health conditions or medications may prevent someone from participating, and those interested will need to provide informed consent before joining the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. 18 to 79 years of age (before the 80th birthday)
  • 2. Presenting with symptoms consistent with AIS
  • 3. Imaging evidence of an anterior circulation occlusion of the Internal Carotid Artery (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1), or proximal M2 segment AND extra-cranial proximal carotid occlusion / severe stenosis related to atherosclerosis requiring treatment on non-invasive imaging ≥70%
  • 4. NIHSS ≥ 4
  • 5. Ability to randomize and start endovascular therapy within 16 hours of stroke onset
  • 6. Pre-stroke mRS score 0-2
  • 7. Ability to obtain signed informed consent
  • 8. ASPECTS Score ≥7 via non-contrast CT or MRI (DWI) for subjects ≤6 hours from stroke onset OR ASPECTS Score ≥7 + infarct core volume \<50 cc quantified by CTP (rCBF\<30%) OR \<25 cc quantified by MRI-DWI (AxBxC/2) for subjects with endovascular therapy starting between \>6h to 16 hours from stroke onset, given the need for antiplatelet therapy.
  • 9. Acute Neurological Deficit with Imaging evidence of Tandem Lesion:
  • Extracranial carotid occlusion (70% to 100% Using NACET criteria) With or without intracranial vascular occlusion
  • 10. Must be ineligible for IV t-PA therapy or have failed IV t-PA therapy
  • Exclusion Criteria:
  • 1. Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test
  • 2. Known severe allergy (more than a rash) to contrast media uncontrolled by medications
  • 3. Refractory hypertension (defined as persistent systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg) despite medication
  • 4. CT evidence of the following conditions:
  • Midline shift or herniation
  • Evidence of intracranial hemorrhage
  • Mass effect with effacement of the ventricles
  • 5. Acute bilateral strokes
  • 6. Contraindication to antiplatelet (Aspirin, Plavix, Ticagrelor, Cangrelor), or thrombolytic therapy, or contrast agents.
  • 7. Intracranial tumors other than small meningioma that does not require surgery for one year post randomization
  • 8. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of \>1.7 or Partial Thromboplastin Time (PTT) \> 3 times of normal
  • 9. Baseline platelet count \<100,000 per microliter (μl)
  • 10. Life expectancy less than one year prior to stroke onset
  • 11. Participation in another randomized clinical trial that could confound the evaluation of the study outcomes
  • 12. Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed
  • 13. Proximal carotid stenosis secondary to dissection or vasculitis (.e.g. Takayasu's Arteritis)

About Mercy Health Ohio

Mercy Health Ohio is a leading healthcare provider dedicated to delivering high-quality, patient-centered care across the region. As a prominent sponsor of clinical trials, Mercy Health Ohio focuses on advancing medical research and innovation to improve health outcomes for diverse populations. With a commitment to ethical practices and rigorous scientific standards, the organization collaborates with healthcare professionals and researchers to develop and implement clinical studies that explore new treatments, therapies, and technologies. By fostering a culture of excellence in research, Mercy Health Ohio aims to contribute significantly to the advancement of medical knowledge and enhance the overall health of the communities it serves.

Locations

Kansas City, Kansas, United States

Sacramento, California, United States

Seattle, Washington, United States

Charleston, South Carolina, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Oklahoma City, Oklahoma, United States

Renton, Washington, United States

Mobile, Alabama, United States

Worcester, Massachusetts, United States

Salt Lake City, Utah, United States

New York, New York, United States

Winston Salem, North Carolina, United States

Miami, Florida, United States

Albany, New York, United States

Glendale, California, United States

Munster, Indiana, United States

Tampa, Florida, United States

Jacksonville, Florida, United States

Salt Lake City, Utah, United States

Morgantown, West Virginia, United States

Winfield, Illinois, United States

New Orleans, Louisiana, United States

Orlando, Florida, United States

Flint, Michigan, United States

Mount Clemens, Michigan, United States

Atlanta, Georgia, United States

Coral Gables, Florida, United States

Columbus, Ohio, United States

Lansing, Michigan, United States

York, Pennsylvania, United States

Delray Beach, Florida, United States

Indianapolis, Indiana, United States

Pittsburgh, Pennsylvania, United States

Toledo, Ohio, United States

Edinburg, Texas, United States

Marietta, Georgia, United States

Piscataway, New Jersey, United States

Saint Louis, Missouri, United States

Lexington, Kentucky, United States

Lansing, Michigan, United States

Bay Shore, New York, United States

Memphis, Tennessee, United States

Houston, Texas, United States

Pomona, California, United States

San Francisco, California, United States

Chicago, Illinois, United States

Shreveport, Louisiana, United States

Kalamazoo, Michigan, United States

Edison, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Osama O Zaidat, MD, MS

Principal Investigator

Mercy Health St. Vincent Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials